Conferences - Results from #500

Viewing 501-520 of 11775 articles

AUA 2024: A Novel Urinary Biomarker for the Detection and Surveillance of Renal Cell Carcinoma

AUA 2024: BCG Unresponsive Disease: How Much Risk can my Patient Tolerate?

AUA 2024: A New Surgical Technology with Femtoseconds Lasers Towards No Thermal Injury in Endoscopic Surgery

AUA 2024: Trends in Usage and Cost of Potassium Citrate and Alternative Alkalizing Agents for Nephrolithiasis

AUA 2024: Very High Risk NMIBC with Variant Histology

AUA 2024: Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand?

AUA 2024: Patient-Reported Toxicity During Intravesical Therapy for Non-Muscle Invasive Bladder Cancer

AUA 2024: Management of Recurrent Low Grade Intermediate Risk Bladder Tumors

AUA 2024: How to Incorporate Enfortumab With or Without Pembrolizumab Into Your Practice

AUA 2024: First Line Therapy for Locally Advanced/Metastatic UC in 2024

AUA 2024: Debate: Lymph Node Dissection for Upper Tract Disease

AUA 2024: Can we Settle the Debate on PLND in Radical Cystectomy?

AUA 2024: Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

AUA 2024: Role of Urinary Markers in Surveillance of NMIBC Patients

AUA 2024: Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients with High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy (PRELUDE Trial)

AUA 2024: Updates on Metastasis Directed Therapy

AUA 2024: Elucidating the Response Rates to Continued Bacillus Calmette-Guerin (BCG) in Patients with BCG Exposed Bladder Cancer: Implications for Clinical Trial Design

AUA 2024: Diagnostic Performance of Fluorescence Cystoscopy Using Oral 5-Aminolevulinic Acid in Transurethral Resection of Bladder Tumor After BCG Treatment

AUA 2024: Photodynamic Diagnosis Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study

AUA 2024: Darolutamide Real-World Doublet and Triplet Utilization in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): US Community Urology Setting

21
22
23
24
25
26
27
28
29
30